Tom 14, Nr 1 (2017)
Nefrokardiologia
Opublikowany online: 2017-06-29
Wyświetlenia strony
537
Wyświetlenia/pobrania artykułu
848
Przewlekła choroba nerek a leczenie przeciwpłytkowe — co warto wiedzieć?
Choroby Serca i Naczyń 2017;14(1):24-29.
Streszczenie
Przewlekła choroba nerek jest jednym z najważniejszych czynników ryzyka rozwoju chorób układu sercowo-naczyniowego, w tym ostrych zespołów wieńcowych. Ich leczenie w większości przypadków polega na wykonaniu przezskórnej angioplastyki wieńcowej i włączeniu podwójnej terapii przeciwpłytkowej. Leczenie przeciwpłytkowe u osób z przewlekłą chorobą nerek jest trudniejsze ze względu na zwiększone ryzyko powikłań zarówno zakrzepowo-zatorowych, jak też krwotocznych. W niniejszej pracy przedstawiono praktyczne zagadnienia związane z leczeniem przeciwpłytkowym u pacjentów z przewlekłą chorobą nerek.
Słowa kluczowe: choroba niedokrwienna sercakwas acetylosalicylowyostry zespół wieńcowyhemodializaleki przeciwpłytkoweprzewlekła choroba nerek
Referencje
- Hill NR, Fatoba ST, Oke JL, et al. Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. PLoS One. 2016; 11(7): e0158765.
- Navarro MA, Gosch KL, Spertus JA, et al. Chronic Kidney Disease and Health Status Outcomes Following Acute Myocardial Infarction. J Am Heart Assoc. 2016; 5(5).
- Tsai TT, Messenger JC, Brennan JM, et al. Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: a report from the linked CathPCI Registry-CMS claims database. J Am Coll Cardiol. 2011; 58(18): 1859–1869.
- Melloni C, Cornel JH, Hafley G, et al. Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial. Eur Heart J Acute Cardiovasc Care. 2016; 5(6): 443–454.
- Wright RS, Reeder GS, Herzog CA, et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med. 2002; 137(7): 563–570.
- Jaroszyńska A, Głowniak A, Brzozowski W, et al. Wpływ przewlekłej choroby nerek na rokowanie i leczenie ostrych zespołów wieńcowych. Chor Serca Naczyń. 2014; 11(2): 74–77.
- Ocak G, Lijfering WM, Verduijn M, et al. Risk of venous thrombosis in patients with chronic kidney disease: identification of high-risk groups. J Thromb Haemost. 2013; 11(4): 627–633.
- Shah SV, Shukla AM, Bose C, et al. Recent advances in understanding the pathogenesis of atherosclerosis in CKD patients. J Ren Nutr. 2015; 25(2): 205–208.
- Smits JH, van der Linden J, Blankestijn PJ, et al. Coagulation and haemodialysis access thrombosis. Nephrol Dial Transplant. 2000; 15(11): 1755–1760.
- Stevens PE, Levin A. Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013; 158(11): 825–830.
- Thijs A, Nanayakkara PWB, Ter Wee PM, et al. Mild-to-moderate renal impairment is associated with platelet activation: a cross-sectional study. Clin Nephrol. 2008; 70(4): 325–331.
- Kshirsagar AV, Craig RG, Moss KL, et al. Periodontal disease adversely affects the survival of patients with end-stage renal disease. Kidney Int. 2009; 75(7): 746–751.
- Rossi M, Campbell KL, Johnson DW, et al. Protein-bound uremic toxins, inflammation and oxidative stress: a cross-sectional study in stage 3-4 chronic kidney disease. Arch Med Res. 2014; 45(4): 309–317.
- Alexopoulos D, Panagiotou A. Oral antiplatelet agents and chronic kidney disease. Hellenic J Cardiol. 2011; 52(6): 509–515.
- Noris M, Benigni A, Boccardo P, et al. Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension. Kidney Int. 1993; 44(2): 445–450.
- Harmon JP, Zimmerman DL, Zimmerman DL. Anticoagulant and antiplatelet therapy in patients with chronic kidney disease: risks versus benefits review. Curr Opin Nephrol Hypertens. 2013; 22(6): 624–628.
- Masson P, Webster AC, Hong M, et al. Chronic kidney disease and the risk of stroke: a systematic review and meta-analysis. Nephrol Dial Transplant. 2015; 30(7): 1162–1169.
- Kim AeJ, Lim HJ, Ro H, et al. Low-dose aspirin for prevention of cardiovascular disease in patients with chronic kidney disease. PLoS One. 2014; 9(8): e104179.
- Baigent C, Landray M, Leaper C, et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis. 2005; 45(3): 473–484.
- Rhee JW, Wiviott SD, Scirica BM, et al. Clinical features, use of evidence-based therapies, and cardiovascular outcomes among patients with chronic kidney disease following non-ST-elevation acute coronary syndrome. Clin Cardiol. 2014; 37(6): 350–356.
- Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324(7329): 71–86.
- Palmer SC, Di Micco L, Razavian M, et al. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012; 156(6): 445–459.
- Major RW, Oozeerally I, Dawson S, et al. Aspirin and cardiovascular primary prevention in non-endstage chronic kidney disease: A meta-analysis. Atherosclerosis. 2016; 251: 177–182.
- Tanrikulu AM, Ozben B, Koc M, et al. Aspirin resistance in patients with chronic renal failure. J Nephrol. 2011; 24(5): 636–646.
- Keltai M, Tonelli M, Mann JFE, et al. CURE Trial Investigators. Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. Eur J Cardiovasc Prev Rehabil. 2007; 14(2): 312–318.
- Dasgupta A, Steinhubl SR, Bhatt DL, et al. CHARISMA Investigators. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). Am J Cardiol. 2009; 103(10): 1359–1363.
- Morel O, Muller C, Jesel L, et al. Impaired platelet P2Y12 inhibition by thienopyridines in chronic kidney disease: mechanisms, clinical relevance and pharmacological options. Nephrol Dial Transplant. 2013; 28(8): 1994–2002.
- Small DS, Wrishko RE, Ernest CS, et al. Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease. J Clin Pharm Ther. 2009; 34(5): 585–594.
- Montalescot G, Silvain J. Ticagrelor in the renal dysfunction subgroup: subjugated or substantiated? Circulation. 2010; 122(11): 1049–1052.
- James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010; 122(11): 1056–1067.
- Magnani G, Storey RF, Steg G, et al. Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. Eur Heart J. 2016; 37(4): 400–408.
- Roffi M, Patrono C, Collet JP, et al. Wytyczne ESC dotyczące postępowania w ostrych zespołach wieńcowych bez przetrwałego uniesienia odcinka ST w 2015 roku. Kardiologia Polska. 2015; 73(12): 1207–1294.
